Schulman P, Davis R, Lee E, Ellerton J, Staszweski H
Cancer Treat Rep. 1987 Jul-Aug;71(7-8):755-7.
A total of 74 patients with relapsed/refractory acute nonlymphocytic leukemia were entered in a phase II trial of diaziquone (AZQ) administered by continuous infusion at a dose of 28 mg/m2 a day for 5 days. Complete remission (CR) was achieved in 12 of the 67 evaluable patients (18%), all occurring in relapsed patients (12 of 55, 22%). There were eight partial responders (one of whom was in the refractory group). Three of these had normal M-1 bone marrow but did not meet peripheral blood criteria for CR. The median duration of CR was 13.6 weeks (range, 4-40+). Nonhematologic toxicity was mild to moderate and easily manageable. Hematologic toxicity was severe or life threatening in all patients. This study confirms the activity of AZQ when given as a continuous infusion to patients with relapsed acute nonlymphocytic leukemia.
共有74例复发/难治性急性非淋巴细胞白血病患者进入一项二阶段试验，该试验采用持续输注的方式给予二氮喹酮（AZQ），剂量为每天28mg/m²，持续5天。67例可评估患者中有12例（18%）实现完全缓解（CR），所有完全缓解均出现在复发患者中（55例中的12例，22%）。有8例部分缓解者（其中1例来自难治组）。其中3例患者骨髓M-1正常，但外周血未达到完全缓解标准。完全缓解的中位持续时间为13.6周（范围为4 - 40 +周）。非血液学毒性为轻度至中度，易于控制。所有患者均出现严重或危及生命的血液学毒性。本研究证实，持续输注AZQ对复发急性非淋巴细胞白血病患者具有活性。
